STOCK TITAN

Axogen (AXGN) director sells 1,647 shares after stock option exercise

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Axogen, Inc. director Wendell Amy McBride exercised stock options and sold the resulting shares. On May 8, 2026, she exercised options covering 1,647 shares of common stock at $14.85 per share, then completed an open-market sale of 1,647 shares at a weighted average price of $42.60 per share, with individual sale prices ranging from $42.50 to $42.62. After these transactions, she directly held 93,826 shares of Axogen common stock.

Positive

  • None.

Negative

  • None.
Insider Wendell Amy McBride
Role null
Sold 1,647 shs ($70K)
Type Security Shares Price Value
Exercise Employee Stock Option (right to purchase) 1,647 $0.00 --
Exercise Common Stock 1,647 $14.85 $24K
Sale Common Stock 1,647 $42.60 $70K
Holdings After Transaction: Employee Stock Option (right to purchase) — 13,353 shares (Direct, null); Common Stock — 95,473 shares (Direct, null)
Footnotes (1)
  1. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $42.50 to $42.62 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. All shares of Axogen, Inc. common stock underlying the board of director's stock option were fully vested on May 31, 2018.
Shares sold 1,647 shares Open-market sale of common stock on May 8, 2026
Sale price $42.60 per share Weighted average sale price; trades from $42.50 to $42.62
Shares exercised 1,647 shares Common stock acquired via option exercise on May 8, 2026
Option exercise price $14.85 per share Exercise price of employee stock option
Shares held after transaction 93,826 shares Total Axogen common stock directly owned after transactions
Option underlying shares 1,647 shares Underlying common shares for exercised employee stock option
Option expiration date June 1, 2027 Expiration of Employee Stock Option (right to purchase)
open-market sale financial
"transaction_action is described as an open-market sale of common stock"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
weighted average sale price financial
"The reported price is a weighted average sale price for multiple trades"
Employee Stock Option (right to purchase) financial
"Security title is Employee Stock Option (right to purchase) underlying common stock"
derivative security financial
"The Form 4 describes the option transaction as an exercise of a derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
underlying security financial
"The option lists Axogen common stock as the underlying security shares"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Wendell Amy McBride

(Last)(First)(Middle)
C/O AXOGEN, INC. 13631 PROGRESS BLVD.
SUITE 400

(Street)
ALACHUA FLORIDA 32615

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Axogen, Inc. [ AXGN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/08/202605/08/2026M1,647A$14.8595,473D
Common Stock05/08/202605/08/2026S1,647D$42.6(1)93,826D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to purchase)$14.8505/08/202605/08/2026M1,647 (2)06/01/2027Common Stock1,647$013,353D
Explanation of Responses:
1. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $42.50 to $42.62 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
2. All shares of Axogen, Inc. common stock underlying the board of director's stock option were fully vested on May 31, 2018.
Remarks:
/s/ Marc Began, as attorney-in-fact for Amy McBride-Wendell05/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Axogen (AXGN) director Wendell Amy McBride report?

Wendell Amy McBride reported exercising stock options for 1,647 Axogen shares and selling 1,647 shares in an open-market transaction. Both the option exercise and sale occurred on May 8, 2026, and involved Axogen common stock.

How many Axogen (AXGN) shares did the director sell and at what price?

She sold 1,647 Axogen common shares in an open-market transaction at a weighted average price of $42.60 per share. Individual trades occurred in a range between $42.50 and $42.62 per share, according to the filing footnote.

What was the option exercise price in the Axogen (AXGN) Form 4 filing?

The reported employee stock options were exercised at $14.85 per share for 1,647 underlying Axogen common shares. This exercise price reflects the strike price of the option, not the market price at which the shares were later sold.

How many Axogen (AXGN) shares does the director hold after these transactions?

Following the reported transactions, Wendell Amy McBride directly held 93,826 shares of Axogen common stock. This holding figure is disclosed in the Form 4 as the total number of common shares owned after the sale and option exercise.

Were the Axogen (AXGN) share sales made in one trade or multiple trades?

The sale was executed in multiple trades at prices ranging from $42.50 to $42.62 per share. The Form 4 reports a weighted average sale price of $42.60 and states that full trade details are available upon request.

What derivative security was involved in the Axogen (AXGN) director’s transaction?

The transaction involved an Employee Stock Option (right to purchase) with a conversion price of $14.85 per share for 1,647 underlying common shares. The options were fully vested and had an expiration date of June 1, 2027.